Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

White House Announces President Trump to Select Dr. Scott Gottlieb to Head FDA

Scott Gottlieb, M.D.

Washington, DC, March 13, 2017 —Laurie McGinley and Carolyn Y. Johnson report in The Washington Post that President Donald J. Trump announced on March 10 that he will nominate Scott Gottlieb, a conservative physician and businessman with deep ties to the pharmaceutical industry, to be commissioner of the Food and Drug Administration.

If confirmed, Gottlieb would bring a strong pro-industry, deregulatory approach to an agency that Trump has criticized as being overly restrictive.

But he is also likely to support one of the agency’s basic functions: to ensure that drugs are proven safe and effective before they are sold.

Dr. Gottlieb’s selection is a victory for the mainstream pharmaceutical industry, which has little appetite for upending the FDA approval process.

Even many Democratic critics of the drug industry, and of Gottlieb himself, privately indicated they strongly preferred him to another frequently mentioned contender, Jim O’Neill, an associate of Silicon Valley billionaire and Trump adviser Peter Thiel.

In a 2014 speech, O’Neill called for allowing drugs to be marketed after they were proven safe, but before they were shown to be effective.

O’Neill’s views and Trump’s recent comments that the FDA’s approval process is “slow and burdensome”— despite data showing that reviews have actually accelerated — caused alarm in some quarters that the agency faced the kind of tectonic reversals now affecting the Environmental Protection Agency.

But while Gottlieb, 44, is not seen as someone interested in dismantling the FDA, he is still likely to try shaking it up in significant ways.

A former deputy FDA commissioner during the George W. Bush administration, he often has faulted the agency in speeches and opinion columns, saying that its excessive rules have stifled competition, especially in its handling of generic approvals for complex medicines.

He also has castigated government efforts to curb “off-label” communications, which involve manufacturers’ touting of drugs for purposes for which they haven’t been approved.

For the full story, click here.